LeMaitre Vascular (LMAT) Competitors

$99.50 +1.33 (+1.35%)

Closing price 04:00 PM Eastern

Extended Trading

$99.42 -0.08 (-0.08%)

As of 04:56 PM Eastern

LMAT vs. GKOS, BLCO, STVN, NVST, and IRTC

Should you buy LeMaitre Vascular stock or one of its competitors? MarketBeat compares LeMaitre Vascular with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with LeMaitre Vascular include Glaukos (GKOS), Bausch + Lomb (BLCO), Stevanato Group (STVN), Envista (NVST), and iRhythm Technologies (IRTC). These companies are all part of the "medical equipment" industry.

How does LeMaitre Vascular compare to Glaukos?

LeMaitre Vascular (NASDAQ:LMAT) and Glaukos (NYSE:GKOS) are both mid-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, media sentiment, institutional ownership, risk and analyst recommendations.

LeMaitre Vascular has higher earnings, but lower revenue than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than LeMaitre Vascular, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LeMaitre Vascular	$249.60M	9.11	$57.73M	$2.71	36.72
Glaukos	$507.44M	16.44	-$187.69M	-$3.28	N/A

LeMaitre Vascular has a net margin of 24.35% compared to Glaukos' net margin of -34.34%. LeMaitre Vascular's return on equity of 15.36% beat Glaukos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LeMaitre Vascular	24.35%	15.36%	9.78%
Glaukos	-34.34%	-6.92%	-5.25%

In the previous week, LeMaitre Vascular had 9 more articles in the media than Glaukos. MarketBeat recorded 15 mentions for LeMaitre Vascular and 6 mentions for Glaukos. LeMaitre Vascular's average media sentiment score of 0.45 beat Glaukos' score of 0.14 indicating that LeMaitre Vascular is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LeMaitre Vascular	4 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Glaukos	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

LeMaitre Vascular currently has a consensus price target of $112.60, suggesting a potential upside of 13.17%. Glaukos has a consensus price target of $144.42, suggesting a potential upside of 1.67%. Given LeMaitre Vascular's higher probable upside, analysts clearly believe LeMaitre Vascular is more favorable than Glaukos.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LeMaitre Vascular	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.75
Glaukos	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86

84.6% of LeMaitre Vascular shares are held by institutional investors. Comparatively, 99.0% of Glaukos shares are held by institutional investors. 7.4% of LeMaitre Vascular shares are held by company insiders. Comparatively, 5.8% of Glaukos shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

LeMaitre Vascular has a beta of 0.6, meaning that its stock price is 40% less volatile than the broader market. Comparatively, Glaukos has a beta of 0.94, meaning that its stock price is 6% less volatile than the broader market.

Summary

LeMaitre Vascular beats Glaukos on 10 of the 16 factors compared between the two stocks.

How does LeMaitre Vascular compare to Bausch + Lomb?

Bausch + Lomb (NYSE:BLCO) and LeMaitre Vascular (NASDAQ:LMAT) are both mid-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, dividends, media sentiment, risk, valuation, institutional ownership and analyst recommendations.

LeMaitre Vascular has lower revenue, but higher earnings than Bausch + Lomb. Bausch + Lomb is trading at a lower price-to-earnings ratio than LeMaitre Vascular, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bausch + Lomb	$5.10B	1.14	-$360M	-$0.62	N/A
LeMaitre Vascular	$249.60M	9.11	$57.73M	$2.71	36.72

LeMaitre Vascular has a net margin of 24.35% compared to Bausch + Lomb's net margin of -4.21%. LeMaitre Vascular's return on equity of 15.36% beat Bausch + Lomb's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bausch + Lomb	-4.21%	3.60%	1.69%
LeMaitre Vascular	24.35%	15.36%	9.78%

In the previous week, LeMaitre Vascular had 10 more articles in the media than Bausch + Lomb. MarketBeat recorded 15 mentions for LeMaitre Vascular and 5 mentions for Bausch + Lomb. LeMaitre Vascular's average media sentiment score of 0.45 beat Bausch + Lomb's score of 0.16 indicating that LeMaitre Vascular is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bausch + Lomb	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
LeMaitre Vascular	4 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Bausch + Lomb currently has a consensus price target of $18.08, suggesting a potential upside of 11.17%. LeMaitre Vascular has a consensus price target of $112.60, suggesting a potential upside of 13.17%. Given LeMaitre Vascular's stronger consensus rating and higher possible upside, analysts plainly believe LeMaitre Vascular is more favorable than Bausch + Lomb.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bausch + Lomb	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21
LeMaitre Vascular	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.75

11.1% of Bausch + Lomb shares are held by institutional investors. Comparatively, 84.6% of LeMaitre Vascular shares are held by institutional investors. 1.5% of Bausch + Lomb shares are held by company insiders. Comparatively, 7.4% of LeMaitre Vascular shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Bausch + Lomb has a beta of 0.59, meaning that its share price is 41% less volatile than the broader market. Comparatively, LeMaitre Vascular has a beta of 0.6, meaning that its share price is 40% less volatile than the broader market.

Summary

LeMaitre Vascular beats Bausch + Lomb on 15 of the 16 factors compared between the two stocks.

How does LeMaitre Vascular compare to Stevanato Group?

Stevanato Group (NYSE:STVN) and LeMaitre Vascular (NASDAQ:LMAT) are both mid-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, dividends, media sentiment, risk, valuation, institutional ownership and analyst recommendations.

84.6% of LeMaitre Vascular shares are held by institutional investors. 0.7% of Stevanato Group shares are held by company insiders. Comparatively, 7.4% of LeMaitre Vascular shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Stevanato Group has higher revenue and earnings than LeMaitre Vascular. Stevanato Group is trading at a lower price-to-earnings ratio than LeMaitre Vascular, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Stevanato Group	€1.34B	4.03	€158.21M	€0.59	30.25
LeMaitre Vascular	$249.60M	9.11	$57.73M	$2.71	36.72

LeMaitre Vascular has a net margin of 24.35% compared to Stevanato Group's net margin of 11.76%. LeMaitre Vascular's return on equity of 15.36% beat Stevanato Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Stevanato Group	11.76%	10.27%	6.08%
LeMaitre Vascular	24.35%	15.36%	9.78%

In the previous week, LeMaitre Vascular had 7 more articles in the media than Stevanato Group. MarketBeat recorded 15 mentions for LeMaitre Vascular and 8 mentions for Stevanato Group. LeMaitre Vascular's average media sentiment score of 0.45 beat Stevanato Group's score of 0.15 indicating that LeMaitre Vascular is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Stevanato Group	0 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
LeMaitre Vascular	4 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

LeMaitre Vascular has a consensus price target of $112.60, suggesting a potential upside of 13.17%. Given LeMaitre Vascular's stronger consensus rating and higher possible upside, analysts plainly believe LeMaitre Vascular is more favorable than Stevanato Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Stevanato Group	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
LeMaitre Vascular	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.75

Stevanato Group has a beta of 0.75, meaning that its share price is 25% less volatile than the broader market. Comparatively, LeMaitre Vascular has a beta of 0.6, meaning that its share price is 40% less volatile than the broader market.

Summary

LeMaitre Vascular beats Stevanato Group on 14 of the 17 factors compared between the two stocks.

How does LeMaitre Vascular compare to Envista?

Envista (NYSE:NVST) and LeMaitre Vascular (NASDAQ:LMAT) are both mid-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, earnings, risk, dividends, media sentiment, institutional ownership, analyst recommendations and profitability.

84.6% of LeMaitre Vascular shares are held by institutional investors. 1.0% of Envista shares are held by insiders. Comparatively, 7.4% of LeMaitre Vascular shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

LeMaitre Vascular has lower revenue, but higher earnings than Envista. LeMaitre Vascular is trading at a lower price-to-earnings ratio than Envista, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Envista	$2.81B	1.38	$47M	$0.41	58.12
LeMaitre Vascular	$249.60M	9.11	$57.73M	$2.71	36.72

LeMaitre Vascular has a net margin of 24.35% compared to Envista's net margin of 2.41%. LeMaitre Vascular's return on equity of 15.36% beat Envista's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Envista	2.41%	7.11%	3.91%
LeMaitre Vascular	24.35%	15.36%	9.78%

In the previous week, LeMaitre Vascular had 5 more articles in the media than Envista. MarketBeat recorded 15 mentions for LeMaitre Vascular and 10 mentions for Envista. Envista's average media sentiment score of 0.56 beat LeMaitre Vascular's score of 0.45 indicating that Envista is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Envista	4 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
LeMaitre Vascular	4 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Envista presently has a consensus price target of $28.83, suggesting a potential upside of 21.00%. LeMaitre Vascular has a consensus price target of $112.60, suggesting a potential upside of 13.17%. Given Envista's higher possible upside, research analysts plainly believe Envista is more favorable than LeMaitre Vascular.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Envista	0 Sell rating(s)	9 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.40
LeMaitre Vascular	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.75

Envista has a beta of 0.92, meaning that its stock price is 8% less volatile than the broader market. Comparatively, LeMaitre Vascular has a beta of 0.6, meaning that its stock price is 40% less volatile than the broader market.

Summary

LeMaitre Vascular beats Envista on 11 of the 17 factors compared between the two stocks.

How does LeMaitre Vascular compare to iRhythm Technologies?

iRhythm Technologies (NASDAQ:IRTC) and LeMaitre Vascular (NASDAQ:LMAT) are both mid-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, earnings, risk, dividends, media sentiment, institutional ownership, analyst recommendations and profitability.

In the previous week, LeMaitre Vascular had 10 more articles in the media than iRhythm Technologies. MarketBeat recorded 15 mentions for LeMaitre Vascular and 5 mentions for iRhythm Technologies. iRhythm Technologies' average media sentiment score of 1.47 beat LeMaitre Vascular's score of 0.45 indicating that iRhythm Technologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
iRhythm Technologies	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
LeMaitre Vascular	4 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

LeMaitre Vascular has a net margin of 24.35% compared to iRhythm Technologies' net margin of -3.53%. LeMaitre Vascular's return on equity of 15.36% beat iRhythm Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
iRhythm Technologies	-3.53%	-10.26%	-1.39%
LeMaitre Vascular	24.35%	15.36%	9.78%

84.6% of LeMaitre Vascular shares are held by institutional investors. 1.0% of iRhythm Technologies shares are held by insiders. Comparatively, 7.4% of LeMaitre Vascular shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

iRhythm Technologies presently has a consensus price target of $193.38, suggesting a potential upside of 69.40%. LeMaitre Vascular has a consensus price target of $112.60, suggesting a potential upside of 13.17%. Given iRhythm Technologies' stronger consensus rating and higher possible upside, research analysts plainly believe iRhythm Technologies is more favorable than LeMaitre Vascular.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iRhythm Technologies	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.93
LeMaitre Vascular	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.75

LeMaitre Vascular has lower revenue, but higher earnings than iRhythm Technologies. iRhythm Technologies is trading at a lower price-to-earnings ratio than LeMaitre Vascular, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iRhythm Technologies	$787.85M	4.76	-$44.55M	-$0.86	N/A
LeMaitre Vascular	$249.60M	9.11	$57.73M	$2.71	36.72

iRhythm Technologies has a beta of 1.33, meaning that its stock price is 33% more volatile than the broader market. Comparatively, LeMaitre Vascular has a beta of 0.6, meaning that its stock price is 40% less volatile than the broader market.

Summary

LeMaitre Vascular beats iRhythm Technologies on 10 of the 17 factors compared between the two stocks.

Get LeMaitre Vascular News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LMAT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LMAT vs. The Competition

Export

Metric	LeMaitre Vascular	MED PRODUCTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.27B	$8.00B	$6.29B	$12.46B
Dividend Yield	1.03%	2.50%	2.79%	5.30%
P/E Ratio	36.72	18.40	20.87	25.61
Price / Sales	9.11	7.72	521.62	63.45
Price / Cash	33.50	16.76	42.94	55.34
Price / Book	5.59	3.67	9.86	6.71
Net Income	$57.73M	$223.05M	$3.55B	$333.77M
7 Day Performance	-7.79%	-1.70%	-0.26%	0.40%
1 Month Performance	-15.24%	3.65%	1.39%	4.03%
1 Year Performance	19.88%	2.10%	41.07%	36.33%

LeMaitre Vascular Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LMAT LeMaitre Vascular	4.5824 of 5 stars	$99.50 +1.4%	$112.60 +13.2%	+17.9%	$2.27B	$249.60M	36.72	490	Insider Trade
GKOS Glaukos	2.5284 of 5 stars	$135.98 -3.0%	$138.85 +2.1%	+48.8%	$8.24B	$507.44M	N/A	1,094	Insider Trade
BLCO Bausch + Lomb	4.2825 of 5 stars	$16.31 0.0%	$18.08 +10.9%	+36.8%	$5.81B	$5.10B	N/A	13,000	News Coverage
STVN Stevanato Group	2.9974 of 5 stars	€17.91 +0.7%	N/A	-28.0%	€5.43B	€1.34B	30.89	6,010	Earnings Report
NVST Envista	3.4662 of 5 stars	$25.82 -2.0%	$28.25 +9.4%	+28.0%	$4.29B	$2.72B	92.20	12,000	Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LMAT) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

LeMaitre Vascular (LMAT) Competitors

LMAT vs. GKOS, BLCO, STVN, NVST, and IRTC

How does LeMaitre Vascular compare to Glaukos?

Summary

How does LeMaitre Vascular compare to Bausch + Lomb?

Summary

How does LeMaitre Vascular compare to Stevanato Group?

Summary

How does LeMaitre Vascular compare to Envista?

Summary

How does LeMaitre Vascular compare to iRhythm Technologies?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LMAT vs. The Competition

LeMaitre Vascular Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

LeMaitre Vascular (LMAT) Competitors

LMAT vs. GKOS, BLCO, STVN, NVST, and IRTC

How does LeMaitre Vascular compare to Glaukos?

Which has stronger valuation & earnings, LMAT or GKOS?

Is LMAT or GKOS more profitable?

Does the media favor LMAT or GKOS?

Do analysts rate LMAT or GKOS?

Do institutionals and insiders hold more shares of LMAT or GKOS?

Which has more risk & volatility, LMAT or GKOS?

Summary

How does LeMaitre Vascular compare to Bausch + Lomb?

Which has higher valuation and earnings, BLCO or LMAT?

Is BLCO or LMAT more profitable?

Does the media refer more to BLCO or LMAT?

Do analysts recommend BLCO or LMAT?

Do insiders & institutionals hold more shares of BLCO or LMAT?

Which has more volatility and risk, BLCO or LMAT?

Summary

How does LeMaitre Vascular compare to Stevanato Group?

Do insiders & institutionals hold more shares of STVN or LMAT?

Which has higher valuation and earnings, STVN or LMAT?

Is STVN or LMAT more profitable?

Does the media refer more to STVN or LMAT?

Do analysts recommend STVN or LMAT?

Which has more volatility and risk, STVN or LMAT?

Summary

How does LeMaitre Vascular compare to Envista?

Do institutionals & insiders hold more shares of NVST or LMAT?

Which has stronger valuation & earnings, NVST or LMAT?

Is NVST or LMAT more profitable?

Does the media refer more to NVST or LMAT?

Do analysts recommend NVST or LMAT?

Which has more risk and volatility, NVST or LMAT?

Summary

How does LeMaitre Vascular compare to iRhythm Technologies?

Does the media refer more to IRTC or LMAT?

Is IRTC or LMAT more profitable?

Do institutionals & insiders hold more shares of IRTC or LMAT?

Do analysts recommend IRTC or LMAT?

Which has stronger valuation & earnings, IRTC or LMAT?

Which has more risk and volatility, IRTC or LMAT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LMAT vs. The Competition

LeMaitre Vascular Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools